Apr 09,2026
April 9, 2026
The 1st CPIC Global Conference on Innovative Drugs 2026 will kick off grandly at the National Exhibition and Convention Center (Shanghai) from July 22 to 24. This is a premier event focused on the globalization of China's innovative drugs, and an open platform for gathering industry wisdom, showcasing cutting-edge achievements, and connecting industrial resources.
Starting today, the conference officially opens the following calls for global biopharmaceutical professionals:
CPIC 2026 | Launch of the Logo for the Inaugural “New Drugs of Major Countries” Global Conference
Apr 09,2026
The inaugural China Pharmaceutical Innovation Conference (CPIC), hosted by Tongxiyì, will be grandly held from July 22 to 24, 2026, at the National Exhibition and Convention Center (Shanghai).
CPIC is benchmarked against the J.P. Morgan Healthcare Conference in the United States, establishing a new paradigm of “Chinese innovation—global translation—Shanghai-based deal-making.” Serving as the “optimal window” for overseas capital and enterprises to gain insight into China’s innovation ecosystem, and as the “core hub” for Chinese pharmaceutical companies to upgrade their international expansion and connect with global markets, the CPIC is poised to become the annual bellwether event for investment and collaboration in the health industry. This year’s conference will feature dozens of specialized sessions, covering a wide range of hot topics and future directions in health-sector innovation, investment, and globalization.
China’s Original “Nuclear” Power Is Rising
Apr 07,2026
In the first few days of April 2026, the Chinese nuclear medicine industry was struck by two momentous developments.
On April 2, the National Medical Products Administration announced on its official website that China’s first independently developed Class 1 innovative radiopharmaceutical—Ruidiao Pharmaceutical’s technetium-99m pertechnetate peptide injection (trade name: Jiluntai), along with its accompanying kit—has officially been approved for market launch.
This represents not only a groundbreaking, original breakthrough in China’s nuclear medicine field, moving from zero to one, but also shatters the nearly 30-year-old monopoly of PET/CT in tumor imaging diagnostics, thereby providing a “Chinese solution” for broad-spectrum SPECT-based tumor imaging worldwide.
Apr 06,2026
The inaugural China Pharmaceutical Innovation Conference (CPIC), hosted by Tongxiyì, will be grandly held from July 22 to 24, 2026, at the National Exhibition and Convention Center (Shanghai).
CPIC is benchmarked against the J.P. Morgan Healthcare Conference in the United States, establishing a new paradigm of “Chinese innovation—global translation—Shanghai transactions.” Serving as the “optimal window” for overseas capital and enterprises to gain insight into China’s innovation ecosystem, and as the “core hub” for Chinese pharmaceutical companies to upgrade their global expansion and connect with the world, the CPIC is poised to become the annual bellwether event for investment and collaboration in the health industry. This year’s conference will feature dozens of specialized sessions, covering a wide range of hot topics and future directions in health-sector innovation, investment, and global development.
A+H: Chinese Biotech Accelerates Its “Dual-Listing” Strategy
Apr 06,2026
The Hong Kong stock IPO market kicked off the first quarter of 2026 on a robust note.
As of February 26, a total of 24 companies had completed Hong Kong stock IPOs this year, up 166.67% year on year, with aggregate fundraising reaching HK$89.226 billion, a year-on-year increase of 1,013.59%. By the end of the first quarter, this figure had surpassed HK$100 billion.
The biopharmaceutical sector has been particularly prominent in this wave of Hong Kong stock IPO activity. As of February 2026, a total of 127 healthcare firms were awaiting listing on both the Hong Kong and A-share markets, marking a record high; of these, 92 are targeting the Hong Kong market, while 35 are planning to list on the A-share market.
China’s New Drugs Return to the M&A Scene
Apr 05,2026
M&A activity in the biopharmaceutical sector is visibly rebounding.
On March 31, two industry giants simultaneously announced acquisition deals: Eli Lilly agreed to acquire sleep-disorder drug company Centessa Pharmaceuticals for up to $7.8 billion, while Biogen shelled out $5.6 billion to acquire Apellis Pharmaceuticals, a developer of immunology and rare-disease therapeutics.
Apr 04,2026
The inaugural China Pharmaceutical Innovation Conference (CPIC), hosted by Tongxiyì, will be grandly held at the National Exhibition and Convention Center (Shanghai) from July 22 to 24, 2026.
CPIC is benchmarked against the J.P. Morgan Healthcare Conference in the United States, establishing a new paradigm of “Chinese innovation—global translation—Shanghai transactions.” Serving as the “optimal window” for overseas capital and enterprises to gain insight into China’s innovation ecosystem, and as the “core hub” for Chinese pharmaceutical companies to upgrade their global expansion and connect with the world, the CPIC is poised to become the annual bellwether event for investment and collaboration in the health industry. A large number of domestic innovative pharmaceutical companies and financial institutions are enthusiastically co-organizing this conference, which will feature dozens of specialized sessions covering a wide range of hot topics and future directions in health-sector innovation, investment, and globalization.
China’s AI-Driven Pharmaceutical Industry Reveals Its “Weight-Loss Ace”
Apr 03,2026
The AI-driven pharmaceutical boom continues to gain momentum, and this time the spotlight has officially shifted to the trillion-dollar weight-loss market.
Last weekend, Insilico Medicine and Eli Lilly announced another collaboration, sending a powerful signal that is widely regarded as a key industry indicator. Although the joint statement did not specify the exact therapeutic indications for the molecule in question, industry insiders generally speculate that the candidate drug—developed on Insilico’s PharmaAI platform—is likely an oral GLP‑1R–targeted weight-loss agent.
Follow or Contact Us
Follow the TONACEA Official WeChat Account and scan the QR code to register. Stay updated with the latest conference news.
Public Account QR Code
Registration QR Code
Conference Service Hotline
© 2026 TONACEA (Shanghai) Technology Development Co., Ltd. All rights reserved. All rights reserved.
